Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: A randomized first human dose trial

Journal of Thrombosis and Haemostasis

Volumn 13, Issue 5, 2015, Pages 743-754

  Chowdary, P ^a   Lethagen, S ^b,c   Friedrich, U ^b   Brand, B ^d   Hay, C ^e   Abdul Karim, F ^f   Klamroth, R ^g   Knoebl, P ^h   Laffan, M ⁱ   Mahlangu, J ^j   Miesbach, W ^k   Dalsgaard Nielsen, J ^l   Martin Salces M ^m   Angchaisuksiri, P ⁿ  

^a ROYAL FREE HOSPITAL   (United Kingdom)

^b NOVO NORDISK A S   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^f National Blood Centre   (Malaysia)

^g VIVANTES HOSPITAL   (Germany)

^h MEDICAL UNIVERSITY OF VIENNA   (Austria)

ⁱ HAMMERSMITH HOSPITAL   (United Kingdom)

^j UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^k Zentrum für Innere Medizin   (Germany)

^l International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^m HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

ⁿ MAHIDOL UNIVERSITY   (Thailand)

more..

Author keywords

Hemophilia; mAb 2021; Pharmacokinetics; Safety; Tissue factor pathway inhibitor

Indexed keywords

ANTITHROMBIN; CONCIZUMAB; D DIMER; FIBRINOGEN; PROTHROMBIN; TISSUE FACTOR PATHWAY INHIBITOR; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2021; PLACEBO;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; BLEEDING; CLINICAL ARTICLE; COMMON COLD; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HEMOSTASIS; HUMAN; INFLUENZA; INJECTION SITE REACTION; MAXIMUM PLASMA CONCENTRATION; MEAN ABSORPTION TIME; MEAN RESIDENCE TIME; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROPHYLAXIS; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SCIATICA; SUPERFICIAL THROMBOPHLEBITIS; THROMBOCYTE COUNT; ADOLESCENT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; MALE; MIDDLE AGED; NORMAL HUMAN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; AREA UNDER CURVE; DOUBLE-BLIND METHOD; HEALTHY VOLUNTEERS; HEMOPHILIA A; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PLACEBOS; YOUNG ADULT;

EID: 84928764693     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12864     Document Type: Article

References (24)

1. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9.
2. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25-32.
3. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, Ludlam CA, Mahlangu JN, Mulder K, Poon MC, Street A. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
4. Ljung R. Prophylactic therapy in haemophilia. Blood Rev 2009; 23: 267-74.
5. Santagostino E, Mancuso ME. Venous access in haemophilic children: choice and management. Haemophilia 2010; 16 (Suppl. 1): 20-4.
6. Hacker MR, Geraghty S, Manco-Johnson M. Barriers to compliance with prophylaxis therapy in haemophilia. Haemophilia 2001; 7: 392-6.
7. Lillicrap D. Extending half-life in coagulation factors: where do we stand? Thromb Res 2008; 122 (Suppl. 4): S2-8.
8. Mahlangu J, Powell JS, Ragni MV, Chowdary P, Josephson NC, Pabinger I, Hanabusa H, Gupta N, Kulkarni R, Fogarty P, Perry D, Shapiro A, Pasi KJ, Apte S, Nestorov I, Jiang H, Li S, Neelakantan S, Cristiano LM, Goyal J, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25.
9. Powell JS, Pasi KJ, Ragni MV, Ozelo MC, Valentino LA, Mahlangu JN, Josephson NC, Perry D, Manco-Johnson MJ, Apte S, Baker RI, Chan GC, Novitzky N, Wong RS, Krassova S, Allen G, Jiang H, Innes A, Li S, Cristiano LM, et al. Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B. N Engl J Med 2013; 369: 2313-23.
10. Mei B, Pan C, Jiang H, Tjandra H, Strauss J, Chen Y, Liu T, Zhang X, Severs J, Newgren J, Chen J, Gu JM, Subramanyam B, Fournel MA, Pierce GF, Murphy JE. Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment. Blood 2010; 116: 270-9.
11. Santagostino E, Negrier C, Klamroth R, Tiede A, Pabinger-Fasching I, Voigt C, Jacobs I, Morfini M. Safety and pharmacokinetics of a novel recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in hemophilia B patients. Blood 2012; 120: 2405-11.
12. Fischer K, Kulkarni R, Bradbury M, Ragni MV, Rangarajan S, Dong Y, Li S, Jiang H, Nugent K, Pierce GF, Allen G. Pharmacokinetics of recombinant factor IX Fc fusion protein (rFIXFc) in pediatric subjects with hemophilia B: an interim analysis of the Kids B-LONG study. Blood 2013; 122: 3599.
13. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallen B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF. Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 2012; 119: 666-72.
14. Negrier C, Knobe K, Tiede A, Giangrande P, Moss J. Enhanced pharmacokinetic properties of a glycoPEGylated recombinant factor IX: a first human dose trial in patients with hemophilia B. Blood 2011; 118: 2695-701.
15. Martinowitz U, Lubetsky A. Phase I/II, open-label, multicenter, safety, efficacy and PK study of a recombinant coagulation factor IX albumin fusion protein (rIX-FP) in subjects with hemophilia B. Thromb Res 2013; 131 (Suppl. 2): S11-4.
16. Tiede A, Brand B, Fischer R, Kavakli K, Lentz SR, Matsushita T, Rea C, Knobe K, Viuff D. Enhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A. J Thromb Haemost 2013; 11: 670-8.
17. Broze GJ Jr, Girard TJ. Tissue factor pathway inhibitor: structure-function. Front Biosci (Landmark Ed) 2012; 17: 262-80.
18. Wood JP, Ellery PE, Maroney SA, Mast AE. Biology of tissue factor pathway inhibitor. Blood 2014; 123: 2934-43.
19. Hilden I, Lauritzen B, Sorensen BB, Clausen JT, Jespersgaard C, Krogh BO, Bowler AN, Breinholt J, Gruhler A, Svensson LA, Petersen HH, Petersen LC, Balling KW, Hansen L, Hermit MB, Egebjerg T, Friederichsen B, Ezban M, Bjorn SE. Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model. Blood 2012; 119: 5871-8.
20. EMA. Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medical products, London, 19 July 2007. EMEA/294648/2007 https://firstclinical.com/regdocs/doc/?db=INT_EMEA_First. Accessed October 31, 2014.
21. Agerso H, Overgaard RV, Petersen MB, Hansen L, Hermit MB, Sorensen MH, Petersen LC, Hilden I. Pharmacokinetics of an anti-TFPI monoclonal antibody (concizumab) blocking the TFPI interaction with the active site of FXa in Cynomolgus monkeys after iv and sc administration. Eur J Pharm Sci 2014; 56: 65-9.
22. Lwaleed BA, Bass PS. Tissue factor pathway inhibitor: structure, biology and involvement in disease. J Pathol 2006; 208: 327-39.
23. Hansen L, Petersen LC, Lauritzen B, Clausen JT, Grell SN, Agerso H, Sorensen BB, Hilden I, Almholt K. Target-mediated clearance and bio-distribution of a monoclonal antibody against the Kunitz-type protease inhibitor 2 domain of Tissue Factor Pathway Inhibitor. Thromb Res 2014; 133: 464-71.
24. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84: 548-58.